menu
    • menu
    [{"orgOrder":0,"company":"Essex Biotechnology","sponsor":"Henlius","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$10.0 million","newsHeadline":"Essex and Henlius Ink Global Co-Development and License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Essex Biotechnology","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Essex Biotechnology \/ Henlius","highestDevelopmentStatusID":"10","companyTruncated":"Essex Biotechnology \/ Henlius"}]

    Find Clinical Drug Pipeline Developments & Deals by Essex Biotechnology

    Menu

    Essex Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Essex Biotechnology

                            China arrow
                            Luxepack
                            Not Confirmed

                            Essex Biotechnology

                            China arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Henlius

                            Deal Size : $25.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Essex and Henlius Ink Global Co-Development and License Agreement to Jointly Develop Bevacizumab for Treatment...

                            Details : Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).

                            Brand Name : HLX04

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            October 15, 2020

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Henlius

                            Deal Size : $25.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth